# A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

> **NCT02683265** · PHASE4 · COMPLETED · sponsor: **Rhodes Pharmaceuticals, L.P.** · enrollment: 158 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Aptensio XR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02683265
- **Lead sponsor:** Rhodes Pharmaceuticals, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-25
- **Primary completion:** 2017-11-02
- **Final completion:** 2018-03-27
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683265, "A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02683265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*